Skip to main content

Table 2 Median rate of measurement and probability of having a gap greater than 12 months between measurements of liver, renal or metabolic function

From: Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study

  Liver (AST/ALT) Renal (Creatinine) Metabolic (Lipids)
  Annual rate of testing, Median (IQR) Subjects with ≥ 1 12-month gap Annual rate of testing, Median (IQR) Subjects with ≥ 1 12-month gap Annual rate of testing, Median (IQR) Subjects with ≥ 1 12-month gap
Overall 2.76 (1.60,3.73) 22 % 2.55 (1.44,3.38) 18 % 1.42 (0.50,2.52) 33 %
  First year of cART 3 (0, 4) -- 2 (0, 4) -- 1 (0, 3) --
  Subsequent years 2.23 (0.31, 3.41) -- 1.78 (0, 3.06) -- 0.85 (0, 2.21) --
Region
  British Columbia 3.25 (0.82,4.56)*** 33 %*** 1.66 (0.41,3.08)*** 23 %*** 1.05 (0.22,2.70)** 24 %***
  Ontario 2.53 (1.37,3.53) 17 % 2.35 (1.33,3.20) 14 % 1.45 (0.50,2.46) 32 %
  Quebec 2.88 (2.08,3.56) 21 % 2.88 (2.07,3.56) 17 % 1.48 (0.66,2.53) 38 %
Gender
  Male 2.80 (1.65,3.77)* 21 %*** 2.59 (1.47,3.41)** 16 %** 1.49 (0.57,2.60)*** 31 %***
  Female 2.60 (1.39,3.56) 29 % 2.33 (1.17,3.28) 24 % 1.02 (0.33,2.09) 43 %
Age       
  <55 2.73 (1.57,3.71)* 23 %** 2.52 (1.43,3.36)** 18 %** 1.39 (0.49,2.48)** 34 %*
  ≥55 3.03 (1.92,4.10) 12 % 2.90 (1.83,3.69) 9 % 1.83 (0.79,2.95) 23 %
Race
  Caucasian 3.03 (1.43,4.16)*** 24 %*** 2.49 (1.07,3.44)*** 21 %*** 1.64 (0.53,2.85)*** 31 %**
  Black 2.73 (1.55,3.74) 26 % 2.27 (1.23,3.17) 18 % 1.01 (0.43,2.09) 45 %
  Aboriginal 2.07 (0.51,3.59) 45 % 1.08 (0.28,2.54) 30 % 0.45 (0.12,1.95) 29 %
  Other 3.38 (2.39,4.40) 15 % 2.62 (1.72,3.49) 12 % 2.03 (0.75,2.98) 25 %
  Unknown 2.64 (1.67,3.43) 20 % 2.63 (1.70,3.39) 16 % 1.41 (0.52,2.34) 34 %
Risk Factor
  MSM 2.97 (1.98,3.92)*** 18 %*** 2.72 (1.81,3.48)*** 15 %*** 1.53 (0.61,2.61)*** 32 %**
  Non-MSM 2.59 (1.26,3.68) 31 % 2.28 (0.97,3.32) 24 % 1.02 (0.31,2.02) 41 %
  IDU 2.13 (0.74,3.66)*** 38 %*** 1.46 (0.41,3.02)*** 29 %*** 0.66 (0.00,1.63)*** 34 %
  Non-IDU 2.89 (1.87,3.84) 21 % 2.67 (1.79,3.48) 16 % 1.45 (0.59,2.52) 36 %
  Endemic 2.75 (1.83,3.62) 22 % 2.65 (1.87,3.44) 20 % 1.21 (0.57,2.12) 50 %***
  Non-Endemic 2.85 (1.63,3.86) 24 % 2.58 (1.42,3.43) 18 % 1.35 (0.46,2.46) 33 %
  Unknown Risk Factor 2.40 (1.35,3.34)*** 15 %*** 2.33 (1.34,3.19)** 14 %* 1.91 (0.67,2.91)*** 21 %***
  Known Risk Factor 2.83 (1.69,3.81) 23 % 2.59 (1.46,3.43) 18 % 1.32 (0.48,2.41) 35 %
Year of cART Initiation
  >2005 2.77 (1.63,3.72) 12 %*** 2.49 (1.21,3.40)* 9 %*** 1.21 (0.33,2.30)*** 23 %***
  2001-2005 2.77 (1.60,3.79) 27 % 2.61 (1.66,3.38) 22 % 1.66 (0.63,2.72) 40 %
  2000 2.53 (1.36,3.47) 53 % 2.51 (1.34,3.25) 37 % 1.45 (0.57,2.70) 49 %
Baseline CD4 count
  <200 cells/mm3 2.83 (1.62,3.78)*** 25 % 2.55 (1.41,3.42)** 19 % 1.44 (0.56,2.59)*** 34 %
  200-350 cells/mm3 2.79 (1.71,3.67) 18 % 2.61 (1.59,3.33) 15 % 1.39 (0.52,2.47) 31 %
  350-500 cells/mm3 2.66 (1.52,3.75) 21 % 2.50 (1.56,3.49) 17 % 1.48 (0.47,2.56) 31 %
  >500 cells/mm3 2.07 (0.82,3.31) 28 % 1.88 (0.00,3.09) 21 % 0.88 (0.00,2.09) 34 %
Baseline Regimen
  NNRTI-Based 2.68 (1.57,3.56)** 19 %*** 2.45 (1.36,3.23)* 16 %** 1.30 (0.47,2.34)*** 34 %***
  Boosted PI-Based 2.94 (1.59,4.01) 22 % 2.60 (1.40,3.52) 17 % 1.58 (0.54,2.73) 28 %
  PI-Based 2.66 (1.58,3.51) 30 % 2.62 (1.70,3.43) 24 % 1.31 (0.42,2.36) 41 %
  Other 2.95 (1.95,3.69) 18 % 2.89 (1.93,3.49) 15 % 1.97 (1.11,2.95) 40 %
Hepatitis C co-infection
  HCV+ 2.38 (0.90,3.86)*** 36 %*** 1.82 (0.55,3.32)*** 28 %*** 0.88 (0.14,2.08)*** 35 %
  HCV- 2.82 (1.77,3.73) 19 % 2.63 (1.67,3.39) 15 % 1.52 (0.60,2.60) 32 %
Hepatitis B co-infection
  HBV+ 2.73 (1.49,3.45) 17 % 2.63 (1.51,3.30) 18 % 1.41 (0.59,2.37) 35 %
  HBV- 2.69 (1.74,3.55) 20 % 2.65 (1.80,3.43) 16 % 1.50 (0.59,2.50) 36 %
HCV and IDU status
  HCV- non-IDU 2.89 (1.89,3.79)*** 20 %*** 2.68 (1.81,3.45)*** 16 %*** 1.45 (0.60,2.49)*** 36 %***
  HCV+ non-IDU 3.31 (2.02,4.54) 25 % 3.12 (1.76,4.29) 18 % 1.78 (0.70,3.18) 34 %
  HCV- IDU 2.90 (1.46,4.08) 23 % 2.30 (1.01,3.25) 15 % 1.21 (0.49,2.32) 23 %
  HCV+ IDU 1.83 (0.62,3.60) 42 % 1.34 (0.27,2.93) 33 % 0.52 (0.00,1.42) 37 %
  Unknown 2.45 (1.34,3.39) 17 % 2.34 (1.31,3.20) 16 % 1.75 (0.57,2.83) 24 %
  1. IDU injection drug use as risk factor for HIV acquisition, HCV+: positive for Hepatitis C; * = <0.01, ** = <0.001, *** = <0.0001